Skip to content
PIL Logo

Lorazepam 1mg and 2.5mg Tablets

Last Updated on eMC 24-Oct-2016 View document  | Genus Pharmaceuticals Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 24-Oct-2016 and displayed until Current

Reasons for adding or updating:

  • Improved presentation of PIL

Updated on 20-Jan-2015 and displayed until 24-Oct-2016

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 08-Aug-2014 and displayed until 20-Jan-2015

Reasons for adding or updating:

  • Change to section 2 - driving and using machines
  • Change to section 6 - date of revision

Updated on 07-Feb-2012 and displayed until 08-Aug-2014

Reasons for adding or updating:

  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery

Updated on 11-Oct-2010 and displayed until 07-Feb-2012

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Genus Pharmaceuticals

Company image

Linthwaite, Huddersfield, West Yorkshire, HD7 5QH, UK


+44 (0)1484847301

Medical Information e-mail

+44 (0)1484842217

Medical Information Direct Line

+44 (0)1484 848164

Customer Care direct line

+44 (0)1484 848200

Out of Hours Telephone

+44 (0)1484 848164

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients


Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue